Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies

被引:87
作者
Molloy, S. A. [1 ]
Rowan, E. N. [1 ]
O'Brien, J. T. [1 ]
McKeith, I. G. [1 ]
Wesnes, K. [1 ]
Burn, D. J. [1 ]
机构
[1] Newcastle Gen Hosp, Ageing & Hlth Wolfson Res Ctr, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
基金
英国医学研究理事会;
关键词
D O I
10.1136/jnnp.2006.098079
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Levodopa (L-dopa) is the gold standard treatment for Parkinson's disease, but a lack of clear efficacy combined with a perceived liability to neuropsychiatric side effects has limited L-dopa use in patients with parkinsonism and dementia. Therefore, the effect of L-dopa on the cognitive profile of dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) is unclear. Aim: To ascertain the acute and long-term effects of L-dopa on aspects of attention and cognition in patients with DLB and PDD, and to compare these with the effects in Parkinson's disease. Method: Baseline cognitive and motor function was assessed off L-dopa in patients with Parkinson's disease (n = 22), PDD (n = 27) and DLB (n = 11) using standard "bedside'' measures and a computerised programme detecting reaction times and accuracy. All patients then underwent an acute L-dopa challenge with subsequent subjective and objective analysis of alertness, verbal recall, reaction times and accuracy. The same parameters were measured after 3 months on L-dopa to assess the prolonged effect. Results: Acute L-dopa challenge considerably improved motor function and subjective alertness in all patients without compromising either reaction times or accuracy, but increased fluctuations were noted in both groups with dementia. Neuropsychiatric scores improved in patients with Parkinson's disease both with and without dementia on L-dopa at 3 months. Although patients with Parkinson's disease also had better mean global cognitive function at this time, mean verbal attention and memory deteriorated, and patients with PDD had slower reaction times in some tests. No patient had a marked deterioration over this time. Patients with DLB did not experience any adverse cognitive or neuropsychiatric effects after 3 months of L-dopa treatment. Conclusion: The use of L-dopa in patients with parkinsonism with dementia does not adversely affect cognitive function.
引用
收藏
页码:1323 / 1328
页数:6
相关论文
共 40 条
[11]   Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease [J].
Clarke, CE ;
Davies, P .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 69 (05) :590-594
[12]  
COOSL R, 2003, NEUROPSYCHOLOGIA, V41, P1431
[13]   Dopaminergic modulation of visual-spatial working memory in Parkinson's disease [J].
Costa, A ;
Peppe, A ;
Dell'Agnello, G ;
Carlesimo, GA ;
Murri, L ;
Bonuccelli, U ;
Caltagirone, C .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2003, 15 (02) :55-66
[14]   THE NEUROPSYCHIATRIC INVENTORY - COMPREHENSIVE ASSESSMENT OF PSYCHOPATHOLOGY IN DEMENTIA [J].
CUMMINGS, JL ;
MEGA, M ;
GRAY, K ;
ROSENBERGTHOMPSON, S ;
CARUSI, DA ;
GORNBEIN, J .
NEUROLOGY, 1994, 44 (12) :2308-2314
[15]   Rivastigmine for dementia associated with Parkinson's disease [J].
Emre, M ;
Aarsland, D ;
Albanese, A ;
Byrne, EJ ;
Deuschl, G ;
De Deyn, PP ;
Durif, F ;
Kulisevsky, J ;
van Laar, T ;
Lees, A ;
Poewe, W ;
Robillard, A ;
Rosa, MM ;
Wolters, E ;
Quarg, P ;
Tekin, S ;
Lane, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2509-2518
[16]  
Fahn S., RECENT DEV PARKINSON, V2, P153, DOI DOI 10.1002/ANA.410220556
[17]   Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease [J].
Fern-Pollak, L ;
Whone, AL ;
Brooks, DJ ;
Mehta, MA .
NEUROPSYCHOLOGIA, 2004, 42 (14) :1917-1926
[18]   Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys [J].
Fernández-Ruiz, J ;
Doudet, D ;
Aigner, TG .
PSYCHOPHARMACOLOGY, 1999, 147 (01) :104-107
[19]  
FernandezRuiz J, 1995, NEUROREPORT, V7, P102, DOI 10.1097/00001756-199512000-00024
[20]  
FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P18